---

title: "Exploring a genetic basis for the metabolic perturbations in ME/CFS using UK Biobank"
tags:
- ‚ûï 2025-12-25
- üß™ Biomarker
- ‚≠ê Landmark
created: '2025-11-28'
published: '2025-11-28'

---


<details>
<summary>Huang et al. (2025)</summary>

- **Authors:** Katherine Huang, Chris Armstrong, et al.
- **Institutes:** Melbourne ME/CFS Collaboration, University of Melbourne, Australia.
- **Publisher:** iScience
- **Link:** [DOI](https://doi.org/10.1016/j.isci.2025.114316)

</details>


## Summary

This research is significant because it provides some of the first large-scale evidence that the metabolic "brokenness" often felt by ME/CFS patients is tied to their genetic makeup. By identifying specific genes like *HSD11B1*, which is involved in processing the stress hormone cortisol, the study validates long-standing theories about the role of the HPA axis in this illness. While it does not point to a single "cause," it suggests that many tiny genetic differences combine to disrupt how the body handles energy and inflammation. This objective data helps move the field toward better patient subtyping and identifies new biological targets for future drug development focused on metabolism and the hormonal system.

## What was researched?

This study aimed to determine if there is a genetic reason for the metabolic abnormalities‚Äîspecifically differences in blood chemicals and fats‚Äîobserved in people with ME/CFS. The researchers performed a metabolite genome-wide association study (mGWAS) to find links between specific DNA variations and the levels of 135 different metabolic markers in the blood.

## Why was it researched?

While many studies have identified metabolic "perturbations" or imbalances in ME/CFS patients, it has remained unclear whether these changes are caused by genetics, environment, or the disease process itself. By using a massive database like the UK Biobank, the researchers sought to identify "typos" in the genetic code (SNPs) that might predispose individuals to the metabolic and neuroendocrine dysfunction characteristic of the illness.

## How was it researched?

This was a large-scale genetic and metabolic data analysis comparing 875 ME/CFS patients with 36,033 healthy controls from the UK Biobank cohort. The team analyzed 135 metabolic biomarkers measured via Nuclear Magnetic Resonance (NMR) spectroscopy, including various cholesterol particles (lipoproteins), fatty acids, and low-molecular-weight metabolites. They used statistical modeling to identify genetic variants that influenced these metabolite levels differently in the patient group compared to the healthy group.

## What has been found?

The study identified 112 significant genetic-metabolic associations unique to the ME/CFS group, highlighting two specific markers‚Äî*HSD11B1* and *SCGN*‚Äîthat are linked to the body‚Äôs stress-response system (the HPA axis) and fat metabolism. Variants in *HSD11B1* were specifically associated with changes in phospholipids within very low-density lipoproteins (VLDL), while variants in *SCGN* affected total fatty acid levels. Additionally, the researchers found that genetic effects on immune-related pathways (involving genes like *ADAP1*, *NR1H3*, and *CD40*) differed between patients and controls, suggesting a combined disruption of lipid metabolism, inflammation, and neurotransmitter transport.

## Discussion

The authors highlight that these findings provide a "molecular rationale" for the diversity of symptoms seen in patients, suggesting that ME/CFS is likely a polygenic condition driven by many small-effect genetic variants. They acknowledge a significant limitation: the UK Biobank relies on self-reported diagnoses, which could lead to the inclusion of misdiagnosed individuals. They also noted that the ME/CFS group had higher rates of high cholesterol and blood pressure medication use compared to the exceptionally healthy control group, which could influence metabolic readings.

## Conclusion & Future Work

The researchers conclude that there is a measurable genetic predisposition to metabolic and neuroendocrine abnormalities in ME/CFS, particularly involving how the body regulates cortisol and fats. They suggest that future research should focus on tissue-specific studies‚Äîsuch as looking directly at liver or fat tissue‚Äîto better understand how these genes disrupt local cortisol regeneration.
